Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of acalabrutinib (ACP-196) in combination with pembrolizumab in hematologic malignancies has completed with results posted i…
-
CLINICAL_TRIALS trial_result · 2022-04-04Clinical Trial Update: Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial update for ONC201 in relapsed/refractory non-Hodgkin's lymphoma, including phase 1 and phase 2 cohorts; study status terminat…
-
CLINICAL_TRIALS trial_result · 2022-02-10Clinical Trial Update: A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor [Phase 2]
A Phase 2 study of the investigational drug INCB050465 in relapsed or refractory Mantle Cell Lymphoma (with or without prior BTK inhibitor) …
-
CLINICAL_TRIALS trial_result · 2022-02-04Clinical Trial Update: Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation [Phase 2]
A Phase 2 trial evaluated bortezomib and rituximab in mantle cell lymphoma patients who had prior stem cell transplantation; results have be…
-
CLINICAL_TRIALS trial_result · 2022-01-28Clinical Trial Update: Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bortezomib, rituximab, and combination chemotherapy in mantle cell lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-01-05Clinical Trial Update: Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating obinutuzumab with ibrutinib in relapsed/refractory mantle cell lymphoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-01-03Clinical Trial Update: Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects [Phase 2]
Phase 2 clinical trial update evaluating Chi-BEAC with auto-HSCT for aggressive lymphomas, reporting on efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A phase 1/2 clinical trial investigates a genetically engineered lymphocyte therapy given after peripheral blood stem cell transplant in pat…
-
CLINICAL_TRIALS trial_result · 2021-12-21Clinical Trial Update: Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 clinical trial update investigating zanubrutinib with rituximab and/or combination chemotherapy for newly diagnosed aggressive B-cel…
-
CLINICAL_TRIALS trial_result · 2021-12-13Clinical Trial Update: Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma [Phase 1, Phase 2]
A multi-phase (Phase 1/2) clinical trial evaluating IM19 CAR-T cells for relapsed/refractory mantle cell lymphoma is ongoing; status current…
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2021-11-11Clinical Trial Update: A Study of OLR in First-line Treatment of Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for OLR as first-line treatment in mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-10-13Clinical Trial Update: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating venetoclax, lenalidomide, and rituximab in relapsed/refractory mantle cell lymphoma (a relapsed non-Hodgkin lymph…
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma [Phase 2]
A phase 2 clinical trial investigating zanubrutinib-based induction and maintenance therapy in young, fit patients with untreated mantle cel…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 trial of enzalutamide for relapsed or refractory mantle cell lymphoma was terminated; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial of ABT-263 in relapsed or refractory lymphoid malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy [Phase 2]
Phase 2 trial assessing safety and efficacy of RAD001 in mantle cell lymphoma patients refractory or intolerant to Velcade therapy has compl…
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 trial evaluating lenalidomide with low-dose dexamethasone and rituximab in rituximab-resistant, non-aggressive B-cell lymphomas; com…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bortezomib, rituximab, dexamethasone with or without temsirolimus in untreated or relapsed Waldenström macroglobu…
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients [Phase 1]
Phase 1/open-label pharmacokinetic study assessing interactions between tazemetostat and CYP enzymes and gastric pH in patients with B-cell …
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study evaluating idelalisib in combination with various chemotherapeutic, immunomodulatory agents, and anti-CD20 antibody in relapse…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab in untreated mantle cell lymphoma. The s…
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD20 radioimmunotherapy before chemotherapy and stem cell transplant in high-risk B-cell malignancies; trial s…
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma [Phase 1]
This Phase I/Ib trial assesses safety and early efficacy signals for nivolumab plus veliparib in patients with advanced solid tumors and agg…